Disruption of virus-host cell interactions and cell signaling pathways as an anti-viral approach against influenza virus infections

Abstract Influenza is still one of the major plagues worldwide with the threatening potential to cause pandemics. In recent years, increasing levels of resistance to the four FDA approved anti-influenza virus drugs have been described. This situation underlines the urgent need for novel anti-virals in preparation for future influenza epidemics or pandemics. Although the anti-virals currently in use target viral factors such as the neuraminidase or the M2 ion channel, there is an increase in pre-clinical approaches that focus on cellular factors or pathways that directly or indirectly interact with virus replication. This does not only include inhibitors of virus-supportive signaling cascades but also interaction blockers of viral proteins with host cell proteins. This review aims to highlight some of these novel approaches that represent a paradigm change in anti-viral strategies against the influenza virus. Although most of these approaches are still in an early phase of preclinical development they might be very promising particularly with respect to the prevention of viral resistance to potential drugs.

[1]  Daniel Becker,et al.  Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication , 2010, Nature.

[2]  A. García-Sastre,et al.  PB1-F2 Expression by the 2009 Pandemic H1N1 Influenza Virus Has Minimal Impact on Virulence in Animal Models , 2010, Journal of Virology.

[3]  Thorsten Wolff,et al.  MEK inhibition impairs influenza B virus propagation without emergence of resistant variants , 2004, FEBS letters.

[4]  K. Nichol,et al.  The effectiveness of vaccination against influenza in healthy, working adults. , 1995, The New England journal of medicine.

[5]  S. Pleschka,et al.  Influenza-virus-induced signaling cascades: targets for antiviral therapy? , 2003, Trends in molecular medicine.

[6]  J. Jansen,et al.  Cistus incanus (CYSTUS052) for treating patients with infection of the upper respiratory tract. A prospective, randomised, placebo-controlled clinical study. , 2009, Antiviral research.

[7]  Y. Lazebnik,et al.  Caspases: enemies within. , 1998, Science.

[8]  H. Pahl,et al.  Activators and target genes of Rel/NF-kappaB transcription factors. , 1999, Oncogene.

[9]  F. Hayden,et al.  Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. , 1992, Current topics in microbiology and immunology.

[10]  S. Apers,et al.  Proanthocyanidins in health care: current and new trends. , 2004, Current medicinal chemistry.

[11]  J. Serkedjieva,et al.  Antioxidant and prooxidant properties of a polyphenol‐rich extract from Geranium sanguineum L. in vitro and in vivo , 2008, Phytotherapy research : PTR.

[12]  Thorsten Wolff,et al.  Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF‐κB‐inhibiting activity , 2007, Cellular microbiology.

[13]  New Millennium Antivirals against Pandemic and Epidemic Influenza: The Neuraminidase Inhibitors , 2002, Antiviral chemistry & chemotherapy.

[14]  L. Aschenbrenner,et al.  Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection. , 2010, The Journal of infectious diseases.

[15]  H. Klenk,et al.  Proteolytic activation of the influenza virus hemagglutinin: The structure of the cleavage site and the enzymes involved in cleavage. , 1981, Virology.

[16]  E. De Clercq,et al.  Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention , 2007, Trends in Pharmacological Sciences.

[17]  R. König,et al.  Human Host Factors Required for Influenza Virus Replication , 2010, Nature.

[18]  Yoshihiro Kawaoka,et al.  oseltamivir: descriptive study , 2022 .

[19]  S. Ludwig Exploited defense: how influenza viruses take advantage of antiviral signaling responses , 2007 .

[20]  C. Widmann,et al.  Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. , 1999, Physiological reviews.

[21]  Kazuhiro Iwai,et al.  Linear ubiquitin assembly complex negatively regulates RIG-I- and TRIM25-mediated type I interferon induction. , 2011, Molecular cell.

[22]  L. Staudt,et al.  Active NF-kappaB signalling is a prerequisite for influenza virus infection. , 2004, The Journal of general virology.

[23]  L. Nencioni,et al.  Inhibition of influenza A virus replication by resveratrol. , 2005, The Journal of infectious diseases.

[24]  L. Aschenbrenner,et al.  DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. , 2007, The Journal of infectious diseases.

[25]  F. Hayden,et al.  Sialidase Fusion Protein as a Novel Broad-Spectrum Inhibitor of Influenza Virus Infection , 2006, Antimicrobial Agents and Chemotherapy.

[26]  H. Klenk,et al.  Proteolytic Activation of Influenza Viruses by Serine Proteases TMPRSS2 and HAT from Human Airway Epithelium , 2006, Journal of Virology.

[27]  Frederick Hayden,et al.  Developing new antiviral agents for influenza treatment: what does the future hold? , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  Stephan Ludwig,et al.  Lung-specific expression of active Raf kinase results in increased mortality of influenza A virus-infected mice , 2004, Oncogene.

[29]  Ronald Frank,et al.  Peptide-Mediated Interference with Influenza A Virus Polymerase , 2007, Journal of Virology.

[30]  Alan R. Saltiel,et al.  Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo , 1999, Nature Medicine.

[31]  B. G. Hale,et al.  The multifunctional NS1 protein of influenza A viruses. , 2008, The Journal of general virology.

[32]  Ralph S. Baric,et al.  Novel Influenza Virus NS1 Antagonists Block Replication and Restore Innate Immune Function , 2008, Journal of Virology.

[33]  J. Ortín,et al.  Development of an HTS Assay for the Search of Anti-influenza Agents Targeting the Interaction of Viral RNA with the NS1 Protein , 2008, Journal of biomolecular screening.

[34]  J. Villard,et al.  Antibacterial and antifungal activities of Cistus incanus and C. monspeliensis leaf extracts. , 1999, Therapie.

[35]  G. Tannock,et al.  Antiviral chemotherapeutic agents against respiratory viruses: where are we now and what’s in the pipeline? , 2004, Current opinion in pulmonary medicine.

[36]  H. Radtke,et al.  Effect of CYSTUS052® and green tea on subjective symptoms in patients with infection of the upper respiratory tract , 2010, Phytotherapy research : PTR.

[37]  Stephan Ludwig,et al.  The proapoptotic influenza A virus protein PB1‐F2 regulates viral polymerase activity by interaction with the PB1 protein , 2008, Cellular microbiology.

[38]  J. Oxford,et al.  In Vivo Prophylactic Activity of QR-435 Against H3N2 Influenza Virus Infection , 2007, American journal of therapeutics.

[39]  Thorsten Wolff,et al.  Ringing the alarm bells: signalling and apoptosis in influenza virus infected cells , 2006, Cellular microbiology.

[40]  K. Thorlund,et al.  Systematic review of influenza resistance to the neuraminidase inhibitors , 2011, BMC infectious diseases.

[41]  H. Mario Geysen,et al.  Novel inhibitor of influenza non-structural protein 1 blocks multi-cycle replication in an RNase L-dependent manner , 2011, The Journal of general virology.

[42]  Isao Kouno,et al.  Antibacterial spectrum of plant polyphenols and extracts depending upon hydroxyphenyl structure. , 2006, Biological & pharmaceutical bulletin.

[43]  R. Gaynor,et al.  The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β , 1998, Nature.

[44]  S. Pleschka,et al.  Caspase 3 activation is essential for efficient influenza virus propagation , 2003, The EMBO journal.

[45]  R. Frank,et al.  Identification of a PA-Binding Peptide with Inhibitory Activity against Influenza A and B Virus Replication , 2009, PloS one.

[46]  R. Lamb,et al.  Controlling influenza virus replication by inhibiting its proton channel. , 2007, Molecular bioSystems.

[47]  H. Narita,et al.  In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705 , 2002, Antimicrobial Agents and Chemotherapy.

[48]  V. Shahin,et al.  Apoptosis leads to a degradation of vital components of active nuclear transport and a dissociation of the nuclear lamina , 2008, Proceedings of the National Academy of Sciences.

[49]  H. Klenk,et al.  Membrane Accumulation of Influenza A Virus Hemagglutinin Triggers Nuclear Export of the Viral Genome via Protein Kinase Cα-mediated Activation of ERK Signaling* , 2006, Journal of Biological Chemistry.

[50]  E. Turpin,et al.  Inhibition of Influenza Virus Infection by a Novel Antiviral Peptide That Targets Viral Attachment to Cells , 2006, Journal of Virology.

[51]  T. Deng,et al.  Hsp90 inhibitors reduce influenza virus replication in cell culture. , 2008, Virology.

[52]  M. Newton,et al.  Drosophila RNAi screen identifies host genes important for influenza virus replication , 2008, Nature.

[53]  Virginia Korte,et al.  A polyphenol rich plant extract, CYSTUS052, exerts anti influenza virus activity in cell culture without toxic side effects or the tendency to induce viral resistance. , 2007, Antiviral research.

[54]  A. Lackenby,et al.  The potential impact of neuraminidase inhibitor resistant influenza , 2008, Current opinion in infectious diseases.

[55]  Hua-Yew Cheng,et al.  Antiviral Properties of Prodelphinidin B-2 3′-O-Gallate from Green Tea Leaf , 2002, Antiviral chemistry & chemotherapy.

[56]  H. Ly,et al.  NF-κB Signaling Differentially Regulates Influenza Virus RNA Synthesis , 2008, Journal of Virology.

[57]  Yu-Ling Huang,et al.  (+)-Vitisin A inhibits influenza A virus-induced RANTES production in A549 alveolar epithelial cells through interference with Akt and STAT1 phosphorylation. , 2008, Planta medica.

[58]  E. Haslam Natural polyphenols (vegetable tannins) as drugs: possible modes of action. , 1996, Journal of natural products.

[59]  Laurent Kaiser,et al.  Influenza virus neuraminidase inhibitors , 2000, The Lancet.

[60]  R. Lamb,et al.  Orthomyxoviridae: The Viruses and Their Replication. , 1996 .

[61]  P. Cohen Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[62]  S. Pleschka,et al.  NF-κB-dependent Induction of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) and Fas/FasL Is Crucial for Efficient Influenza Virus Propagation* , 2004, Journal of Biological Chemistry.

[63]  Irene Ramos,et al.  The Influenza Virus Protein PB1-F2 Inhibits the Induction of Type I Interferon at the Level of the MAVS Adaptor Protein , 2011, PLoS pathogens.

[64]  F. Aoki,et al.  Influenza Virus Susceptibility and Resistance to Oseltamivir , 2005, Antiviral therapy.

[65]  Johannes G. Bode,et al.  Influenza A Virus Inhibits Type I IFN Signaling via NF-κB-Dependent Induction of SOCS-3 Expression , 2008, PLoS pathogens.

[66]  S. Pleschka,et al.  MEK-Specific Inhibitor U0126 Blocks Spread of Borna Disease Virus in Cultured Cells , 2001, Journal of Virology.

[67]  Rong Wang,et al.  Influenza Virus PB1-F2 Protein Induces Cell Death through Mitochondrial ANT3 and VDAC1 , 2005, PLoS pathogens.

[68]  Y. Lazebnik,et al.  Caspases Disrupt the Nuclear-Cytoplasmic Barrier , 2000, The Journal of cell biology.

[69]  D. Viemann,et al.  H5N1 Virus Activates Signaling Pathways in Human Endothelial Cells Resulting in a Specific Imbalanced Inflammatory Response , 2011, The Journal of Immunology.

[70]  Rei-Lin Kuo,et al.  The CPSF30 Binding Site on the NS1A Protein of Influenza A Virus Is a Potential Antiviral Target , 2006, Journal of Virology.

[71]  C. Lam,et al.  The use of an herbal formula by hospital care workers during the severe acute respiratory syndrome epidemic in Hong Kong to prevent severe acute respiratory syndrome transmission, relieve influenza-related symptoms, and improve quality of life: a prospective cohort study. , 2005, Journal of alternative and complementary medicine.

[72]  S. Pleschka,et al.  Inhibitory activity of a standardized elderberry liquid extract against clinically-relevant human respiratory bacterial pathogens and influenza A and B viruses , 2011, BMC complementary and alternative medicine.

[73]  O. Planz,et al.  Influenza viruses and the NF-κB signaling pathway – towards a novel concept of antiviral therapy , 2008, Biological chemistry.

[74]  R. Lamb,et al.  The M2 Proton Channels of Influenza A and B Viruses* , 2006, Journal of Biological Chemistry.

[75]  J. Oxford,et al.  Preclinical In Vitro Activity of QR-435 Against Influenza A Virus as a Virucide and in Paper Masks for Prevention of Viral Transmission , 2007, American journal of therapeutics.

[76]  C. Ehrhardt,et al.  A new player in a deadly game: influenza viruses and the PI3K/Akt signalling pathway , 2009, Cellular microbiology.

[77]  Y. Henis,et al.  Clustering of Raft-Associated Proteins in the External Membrane Leaflet Modulates Internal Leaflet H-Ras Diffusion and Signaling , 2006, Molecular and Cellular Biology.

[78]  T. Shimamura,et al.  Inhibition of the infectivity of influenza virus by tea polyphenols. , 1993, Antiviral research.

[79]  A. Nahrstedt,et al.  Proanthocyanidins from Cistus incanus , 1993 .

[80]  N. Bovin,et al.  Multimeric glycotherapeutics: New paradigm , 2004, Glycoconjugate Journal.

[81]  S. Inoue,et al.  Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. , 2009, Cell host & microbe.

[82]  J. Tomassini,et al.  A novel antiviral agent which inhibits the endonuclease of influenza viruses , 1996, Antimicrobial agents and chemotherapy.

[83]  N. Hacohen,et al.  A Physical and Regulatory Map of Host-Influenza Interactions Reveals Pathways in H1N1 Infection , 2009, Cell.

[84]  J. Serkedjieva,et al.  Protective efficacy of an aerosol preparation, obtained from Geranium sanguineum L., in experimental influenza infection. , 2008, Pharmazie.

[85]  A. Scalbert Antimicrobial properties of tannins , 1991 .

[86]  D. Viemann,et al.  Essential Impact of NF-κB Signaling on the H5N1 Influenza A Virus-Induced Transcriptome1 , 2009, The Journal of Immunology.

[87]  Stephan Ludwig,et al.  Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo. , 2011, Antiviral research.

[88]  Julie L. McAuley,et al.  The Effects of Influenza A Virus PB1-F2 Protein on Polymerase Activity Are Strain Specific and Do Not Impact Pathogenesis , 2009, Journal of Virology.

[89]  T. Wolff,et al.  CRK adaptor protein expression is required for efficient replication of avian influenza A viruses and controls JNK‐mediated apoptotic responses , 2010, Cellular microbiology.

[90]  C. Ehrhardt,et al.  CYSTUS052, a polyphenol-rich plant extract, exerts anti-influenza virus activity in mice. , 2007, Antiviral research.

[91]  S. Pleschka,et al.  Inhibition of influenza virus-induced NF-kappaB and Raf/MEK/ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivo. , 2011, Antiviral research.

[92]  R. Gaynor,et al.  The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. , 1998, Nature.

[93]  S. Ludwig Influenza viruses and MAP kinase cascades – Novel targets for an antiviral intervention? , 2007 .

[94]  M. D. de Jong,et al.  Neuraminidase Inhibitors and their Role in Avian and Pandemic Influenza , 2005, Antiviral therapy.

[95]  M. Karin,et al.  JNK2 and IKKbeta are required for activating the innate response to viral infection. , 1999, Immunity.

[96]  A. Nahrstedt,et al.  Flavan-3-ols and proanthocyanidins from Cistus incanus , 1991 .

[97]  David J. Adams,et al.  The IFITM Proteins Mediate Cellular Resistance to Influenza A H1N1 Virus, West Nile Virus, and Dengue Virus , 2009, Cell.

[98]  N. Cox,et al.  Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. , 2006, JAMA.

[99]  R. Wagner,et al.  Avian and 1918 Spanish Influenza A Virus NS1 Proteins Bind to Crk/CrkL Src Homology 3 Domains to Activate Host Cell Signaling* , 2008, Journal of Biological Chemistry.

[100]  Liliana Jiménez,et al.  Polyphenols: food sources and bioavailability. , 2004, The American journal of clinical nutrition.

[101]  Masato Kubo,et al.  Suppressors of cytokine signaling and immunity , 2003, Nature Immunology.

[102]  R. Frank,et al.  Disruption of the Viral Polymerase Complex Assembly as a Novel Approach to Attenuate Influenza A Virus* , 2010, The Journal of Biological Chemistry.

[103]  Thorsten Wolff,et al.  Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade , 2001, Nature Cell Biology.

[104]  B. Seong,et al.  Antiviral effect of catechins in green tea on influenza virus. , 2005, Antiviral research.

[105]  M. Peiris Pathogenesis of avian flu H5N1 and SARS. , 2006, Novartis Foundation symposium.

[106]  P. Palese,et al.  Influenza A virus PB1-F2: a small protein with a big punch. , 2007, Cell host & microbe.